ID   M14-CDM
AC   CVCL_ZZ71
SY   M14 CDM; M14-Chemically Defined Medium
DR   cancercelllines; CVCL_ZZ71
DR   Wikidata; Q102114489
RX   PubMed=1260767;
RX   PubMed=6386801;
CC   Group: Serum/protein free medium cell line.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Right buttock, hypodermis; UBERON=UBERON_0013691+UBERON_0002072.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1395 ! M14
SX   Male
AG   33Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=1260767;
RA   Chee D.O., Boddie A.W. Jr., Roth J.A., Holmes E.C., Morton D.L.;
RT   "Production of melanoma-associated antigen(s) by a defined malignant
RT   melanoma cell strain grown in chemically defined medium.";
RL   Cancer Res. 36:1503-1509(1976).
//
RX   PubMed=6386801; DOI=10.1016/S0021-9258(18)90807-0;
RA   Bumol T.F., Walker L.E., Reisfeld R.A.;
RT   "Biosynthetic studies of proteoglycans in human melanoma cells with a
RT   monoclonal antibody to a core glycoprotein of chondroitin sulfate
RT   proteoglycans.";
RL   J. Biol. Chem. 259:12733-12741(1984).
//